Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
Authors:
- 1 September 2006
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (9) , 1147-1153
Abstract
Objectives: To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration 3 from 12 centres were randomly assigned to 24 weeks’ treatment with SSZ 2 g/day or placebo. The primary outcome variable was the change in BASDAI over 6 months. Secondary outcomes included measures of spinal pain, physical function and inflammation. Results: 230 patients (50% men, age range 18–64 years, 67% human leucocyte antigen B27 positive) were treated with either SSZ 2×1 g/day or placebo for 6 months. Enthesitis was found in 50%, and peripheral arthritis in 47% of the patients. The mean (SD) BASDAI dropped markedly in both groups: by 3.7 (2.7) and 3.8 (2.4), respectively, as did most secondary outcome measures. No noticeable difference in treatment was observed between groups. Patients with IBP and no peripheral arthritis had significantly (p = 0.03) more benefit with SSZ (BASDAI 5.1 (1.3) to 2.8 (2.3)) than with placebo (5.2 (1.6) to 3.8 (2.4)). Spinal pain (p = 0.03) and morning stiffness (p = 0.05) improved with SSZ in these patients, but other secondary outcomes were not markedly different. Conclusion: SSZ was no better than placebo for the treatment of the signs and symptoms of uSpA; however, SSZ was more effective than placebo in the subgroup of patients with IBP and no peripheral arthritis.Keywords
This publication has 28 references indexed in Scilit:
- Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trialArthritis & Rheumatism, 2005
- Sulfasalazine for ankylosing spondylitis2005
- The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity IndexArthritis Care & Research, 2004
- Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitisEye, 2000
- Sulfasalazine in the treatment of ankylosing spondylitisArthritis & Rheumatism, 1988
- Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.BMJ, 1986
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984
- The risk of developing ankylosing spondylitis in HLA‐B27 positive individualsArthritis & Rheumatism, 1984